Recent advances in targeted therapies for mutated EGFR, ALK, ROS1 and KRASG12C have led to better treatment outcomes in NSCLC patients in general, but also show promising results in patients with brain metastases7,.8 This evidence concerns the gene EGFR and non-small cell lung carcinoma.